van Overbeeke, Eline http://orcid.org/0000-0003-0073-9350
Forrester, Valérie
Simoens, Steven
Huys, Isabelle
Funding for this research was provided by:
Innovative Medicines Initiative (Grant agreement No 115966)
Article History
First Online: 28 August 2020
Declarations
:
: This study was funded by the Patient Preferences in Benefit–Risk Assessments during the Drug Life Cycle (PREFER) project. The PREFER project has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This text and its contents reflect the PREFER project's view and not the view of IMI, the European Union, or EFPIA.
: The authors have no competing interests to declare.
: Ethical approval was obtained by the Education Guidance Committee for Medical Ethics (OBC) of the University of Leuven (MP011130).
: All interviewees provided written informed consent prior to the focus groups.
: All interviewees provided written informed consent for the use of the collected pseudonymized data for publication.